FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158366593> ?p ?o ?g. }

• W2158366593 endingPage "319" @default.
• W2158366593 startingPage "311" @default.
• W2158366593 abstract "Abstract Purpose: BIBF 1120 is an oral, potent angiokinase inhibitor targeting receptors of the vascular endothelial growth factors, platelet-derived growth factors, and fibroblast growth factors. This phase I, accelerated titration study assessed the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamic effects of BIBF 1120. Patients and Methods: Sixty-one patients with advanced cancers received BIBF 1120 in successive cohorts. Twenty-five received 50 to 450 mg once daily and 36 received 150 to 300 mg twice daily in 4-week treatment courses interspersed by 1 week of washout. Dynamic contrast-enhanced magnetic resonance imaging assessed antiangiogenic effect in 42 patients. Results: Most frequent BIBF 1120–related adverse events were mostly mild to moderate (Common Toxicity Criteria grade 1-2) nausea (68.9%), vomiting (45.9%), and diarrhea (44.3%). The majority of dose-limiting adverse events of Common Toxicity Criteria grade 3 or 4 were reversible liver enzyme elevations. The maximum tolerated dose was 250 mg of BIBF 1120 for once and twice daily dosing. BIBF 1120 was absorbed moderately fast (tmax = 1-3 hours at steady state), with no deviation from dose linearity and no decrease of exposure over time. The gMean terminal half-life was from 13 to 19 hours. One complete and two partial responses occurred in patients with renal cell cancer (n = 2) and colorectal cancer (n = 1). Dynamic contrast-enhanced magnetic resonance imaging showed a significant reduction in tumor blood flow in 55% of evaluable patients. Conclusions: BIBF 1120 dosed continuously displayed a favorable safety and pharmacokinetics profile, and first efficacy signals were observed. Twice daily dosing permitted increased drug exposure without additional toxicity. Two hundred milligrams BIBF 1120 twice daily is the recommended dose for phase II monotherapy studies. Clin Cancer Res; 16(1); 311–9" @default.
• W2158366593 created "2016-06-24" @default.
• W2158366593 creator A5010204610 @default.
• W2158366593 creator A5027572658 @default.
• W2158366593 creator A5038611848 @default.
• W2158366593 creator A5043260409 @default.
• W2158366593 creator A5044081105 @default.
• W2158366593 creator A5047860622 @default.
• W2158366593 creator A5063780067 @default.
• W2158366593 creator A5064684263 @default.
• W2158366593 creator A5067135726 @default.
• W2158366593 creator A5072216201 @default.
• W2158366593 creator A5074420045 @default.
• W2158366593 creator A5091030888 @default.
• W2158366593 date "2010-01-01" @default.
• W2158366593 modified "2023-10-05" @default.
• W2158366593 title "Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors" @default.
• W2158366593 cites W1495287184 @default.
• W2158366593 cites W1604140953 @default.
• W2158366593 cites W1977999028 @default.
• W2158366593 cites W2004769542 @default.
• W2158366593 cites W2008119533 @default.
• W2158366593 cites W2012859221 @default.
• W2158366593 cites W2034074778 @default.
• W2158366593 cites W2042098439 @default.
• W2158366593 cites W2049360086 @default.
• W2158366593 cites W2061350341 @default.
• W2158366593 cites W2068014745 @default.
• W2158366593 cites W2076415360 @default.
• W2158366593 cites W2077129920 @default.
• W2158366593 cites W2081953717 @default.
• W2158366593 cites W2089756110 @default.
• W2158366593 cites W2095867755 @default.
• W2158366593 cites W2112940666 @default.
• W2158366593 cites W2116177733 @default.
• W2158366593 cites W2130616229 @default.
• W2158366593 cites W2142752401 @default.
• W2158366593 cites W2149026055 @default.
• W2158366593 cites W2165760078 @default.
• W2158366593 cites W2324677651 @default.
• W2158366593 doi "https://doi.org/10.1158/1078-0432.ccr-09-0694" @default.
• W2158366593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20028771" @default.
• W2158366593 hasPublicationYear "2010" @default.
• W2158366593 type Work @default.
• W2158366593 sameAs 2158366593 @default.
• W2158366593 citedByCount "153" @default.
• W2158366593 countsByYear W21583665932012 @default.
• W2158366593 countsByYear W21583665932013 @default.
• W2158366593 countsByYear W21583665932014 @default.
• W2158366593 countsByYear W21583665932015 @default.
• W2158366593 countsByYear W21583665932016 @default.
• W2158366593 countsByYear W21583665932017 @default.
• W2158366593 countsByYear W21583665932018 @default.
• W2158366593 countsByYear W21583665932019 @default.
• W2158366593 countsByYear W21583665932020 @default.
• W2158366593 countsByYear W21583665932021 @default.
• W2158366593 countsByYear W21583665932022 @default.
• W2158366593 countsByYear W21583665932023 @default.
• W2158366593 crossrefType "journal-article" @default.
• W2158366593 hasAuthorship W2158366593A5010204610 @default.
• W2158366593 hasAuthorship W2158366593A5027572658 @default.
• W2158366593 hasAuthorship W2158366593A5038611848 @default.
• W2158366593 hasAuthorship W2158366593A5043260409 @default.
• W2158366593 hasAuthorship W2158366593A5044081105 @default.
• W2158366593 hasAuthorship W2158366593A5047860622 @default.
• W2158366593 hasAuthorship W2158366593A5063780067 @default.
• W2158366593 hasAuthorship W2158366593A5064684263 @default.
• W2158366593 hasAuthorship W2158366593A5067135726 @default.
• W2158366593 hasAuthorship W2158366593A5072216201 @default.
• W2158366593 hasAuthorship W2158366593A5074420045 @default.
• W2158366593 hasAuthorship W2158366593A5091030888 @default.
• W2158366593 hasConcept C111113717 @default.
• W2158366593 hasConcept C112705442 @default.
• W2158366593 hasConcept C126322002 @default.
• W2158366593 hasConcept C126894567 @default.
• W2158366593 hasConcept C197934379 @default.
• W2158366593 hasConcept C29730261 @default.
• W2158366593 hasConcept C71924100 @default.
• W2158366593 hasConcept C90924648 @default.
• W2158366593 hasConcept C98274493 @default.
• W2158366593 hasConceptScore W2158366593C111113717 @default.
• W2158366593 hasConceptScore W2158366593C112705442 @default.
• W2158366593 hasConceptScore W2158366593C126322002 @default.
• W2158366593 hasConceptScore W2158366593C126894567 @default.
• W2158366593 hasConceptScore W2158366593C197934379 @default.
• W2158366593 hasConceptScore W2158366593C29730261 @default.
• W2158366593 hasConceptScore W2158366593C71924100 @default.
• W2158366593 hasConceptScore W2158366593C90924648 @default.
• W2158366593 hasConceptScore W2158366593C98274493 @default.
• W2158366593 hasIssue "1" @default.
• W2158366593 hasLocation W21583665931 @default.
• W2158366593 hasLocation W21583665932 @default.
• W2158366593 hasOpenAccess W2158366593 @default.
• W2158366593 hasPrimaryLocation W21583665931 @default.
• W2158366593 hasRelatedWork W1758514097 @default.
• W2158366593 hasRelatedWork W1997101420 @default.
• W2158366593 hasRelatedWork W2010116591 @default.
• W2158366593 hasRelatedWork W2090099591 @default.

• next